Nuveen LLC Takes $589,000 Position in Sana Biotechnology, Inc. $SANA

Key Points

• Nuveen LLC acquired 350,539 shares of Sana Biotechnology, valued at approximately $589,000, representing an ownership of 0.16% as of the end of the last quarter.
• A variety of institutional investors have significantly increased their stakes in Sana Biotechnology, including Millennium Management with a 604.8% increase and Two Sigma Advisers with a 677.0% increase in the 4th quarter.
• Analysts have an average rating of "Buy" on Sana shares with a consensus target price of $8.00, while the stock's price currently stands at $2.99.

Nuveen LLC purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 350,539 shares of the company's stock, valued at approximately $589,000. Nuveen LLC owned approximately 0.16% of Sana Biotechnology as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its position in shares of Sana Biotechnology by 229.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock worth $25,000 after purchasing an additional 10,548 shares in the last quarter. Ameriprise Financial Inc. bought a new position in shares of Sana Biotechnology during the fourth quarter worth $29,000. Pallas Capital Advisors LLC bought a new position in shares of Sana Biotechnology during the first quarter worth $29,000. BNP Paribas Financial Markets bought a new position in shares of Sana Biotechnology during the fourth quarter worth $34,000. Finally, Focus Partners Wealth bought a new position in shares of Sana Biotechnology during the fourth quarter worth $35,000. 88.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Morgan Stanley assumed coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 price objective on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 price objective on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Sana Biotechnology presently has a consensus rating of "Buy" and an average price target of $8.00.

Sana Biotechnology Price Performance

NASDAQ:SANA traded down $0.02 on Friday, hitting $2.96. 3,612,816 shares of the company's stock were exchanged, compared to its average volume of 4,792,999. The firm has a 50-day moving average price of $3.71 and a 200-day moving average price of $2.70. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $7.30. The company has a market cap of $703.92 million, a P/E ratio of -2.79 and a beta of 1.88.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. On average, research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.